Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Idera Pharmaceuticals, Inc.
Eligible subjects will be enrolled and assigned to one of five dose cohorts. Treatment will be administered by subcutaneous injection until progression or intolerable toxicity.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL) of non-GCB subtype, established according to the World Health Organization (WHO) criteria that has been tested for the MyD88 L265P mutation.
You may not be if
1. Be at least 18 years of age
2. Agree to use contraception
1. Is nursing or pregnant
2. DLBCL of GCB subtype
3. Has BMI \> 34.9 kg/m2
4. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg)
